News and Comments

A NEW MUCH IMPROVED AGENUS?

  Tuesday, April 29, 2014

In February 2014 Agenus (AGEN) acquired 4-Antibody and with it its breakthrough Retrocyte Display technology. Two months later, Agenus signed a collaboration and license agreement with Merck, for the discovery and development of therapeutic antibodies to immune checkpoints for the treatment of cancer through the newly acquired Retrocyte Display technology.  More...

GILEAD SOVALDI IS THE SOLUTION NOT THE PROBLEM

  Monday, April 28, 2014

Why sell side investors select to short outperforming firms when they know they are betting against growth firms expected to announce extraordinarily positive game changing news?    More...

CYTOKINETICS: THE MOMENT OF HALF THE TRUTH

  Friday, April 25, 2014

Bad news has come from Cytokinetics' (CYTK) top-line results of BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). Bottom line, BENEFIT-ALS trial did not achieve its primary efficacy endpoint, the mean change from baseline in the ALS Functional Rating Scale in its revised form (ALSFRS-R) on tirasemtiv versus placebo (-2.98 points in the tirasemtiv group versus -2.40 points in the placebo group, p = 0.11). Another ambitious attempt to decrease some of ALS burden on the sufferers has disappointed.  
 More...


Recent News_and_Comments


Archive


Tags